ATE284538T1 - Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzen - Google Patents

Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzen

Info

Publication number
ATE284538T1
ATE284538T1 AT99961552T AT99961552T ATE284538T1 AT E284538 T1 ATE284538 T1 AT E284538T1 AT 99961552 T AT99961552 T AT 99961552T AT 99961552 T AT99961552 T AT 99961552T AT E284538 T1 ATE284538 T1 AT E284538T1
Authority
AT
Austria
Prior art keywords
disease
complex
level
alzheimer
biological sample
Prior art date
Application number
AT99961552T
Other languages
English (en)
Inventor
Jordan L Holtzman
Original Assignee
Jordan L Holtzman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jordan L Holtzman filed Critical Jordan L Holtzman
Application granted granted Critical
Publication of ATE284538T1 publication Critical patent/ATE284538T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99961552T 1998-10-30 1999-10-29 Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzen ATE284538T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10639898P 1998-10-30 1998-10-30
US12356499P 1999-03-10 1999-03-10
PCT/US1999/025593 WO2000026251A2 (en) 1998-10-30 1999-10-29 A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX

Publications (1)

Publication Number Publication Date
ATE284538T1 true ATE284538T1 (de) 2004-12-15

Family

ID=26803625

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961552T ATE284538T1 (de) 1998-10-30 1999-10-29 Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzen

Country Status (12)

Country Link
US (3) US6972318B1 (de)
EP (1) EP1125135B1 (de)
JP (1) JP4571310B2 (de)
AT (1) ATE284538T1 (de)
AU (1) AU764713B2 (de)
CA (1) CA2348545C (de)
DE (1) DE69922535T2 (de)
IL (2) IL142852A0 (de)
MX (1) MXPA01004317A (de)
NO (1) NO331974B1 (de)
NZ (1) NZ511589A (de)
WO (1) WO2000026251A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522951A (en) * 2000-05-24 2004-11-26 Jordan Loyal Holtzman Biphenylmethane compounds as agents for increasing brain chaperonin levels
US7094884B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
ES2294196T3 (es) * 2002-12-20 2008-04-01 F. Hoffmann-La Roche Ag Metodos para elaborar y utilizar complejos solubles de proteinas diana y chaperonas peptil prolil isomerasas.
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
JP4981305B2 (ja) * 2005-11-11 2012-07-18 公益財団法人大阪バイオサイエンス研究所 アルツハイマー病の発症リスク又はアルツハイマー病発症予後の予測方法
US8592844B2 (en) * 2010-01-29 2013-11-26 Nitto Denko Corporation Light-emitting diode device
JP6227523B2 (ja) * 2011-04-05 2017-11-08 アルファベータ・エービーＡｌｐｈａＢｅｔａ ＡＢ 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
CA2879103A1 (en) * 2012-07-13 2014-01-16 Jordan L. Holtzman Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease
WO2018067854A1 (en) * 2016-10-06 2018-04-12 Ramp Research, Llc Methods, compositions, and kits involving alteration of the chaperone protein axis in a subject

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
EP0683234B2 (de) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5707821A (en) * 1995-06-07 1998-01-13 Athena Neurosciences, Inc. Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease
JPH09178743A (ja) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
CA2313236A1 (en) 1997-12-10 1999-06-17 Nps Pharmaceuticals, Inc. Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides, corresponding acids, and uses

Also Published As

Publication number Publication date
NZ511589A (en) 2005-02-25
WO2000026251A2 (en) 2000-05-11
US20060024759A1 (en) 2006-02-02
US7927824B2 (en) 2011-04-19
MXPA01004317A (es) 2003-06-06
NO20012114L (no) 2001-06-14
DE69922535D1 (de) 2005-01-13
US6972318B1 (en) 2005-12-06
AU1810500A (en) 2000-05-22
JP4571310B2 (ja) 2010-10-27
EP1125135B1 (de) 2004-12-08
WO2000026251A9 (en) 2001-01-04
IL142852A0 (en) 2002-03-10
IL142852A (en) 2010-05-31
EP1125135A2 (de) 2001-08-22
AU764713B2 (en) 2003-08-28
US20110256569A1 (en) 2011-10-20
WO2000026251A3 (en) 2000-08-10
US8211658B2 (en) 2012-07-03
NO331974B1 (no) 2012-05-14
DE69922535T2 (de) 2005-05-12
NO20012114D0 (no) 2001-04-27
CA2348545C (en) 2012-08-21
CA2348545A1 (en) 2000-05-11
JP2002528555A (ja) 2002-09-03

Similar Documents

Publication Publication Date Title
Sharp Alpha-1-antitrypsin deficiency
Walker et al. Changes in activated protein C resistance during normal pregnancy
ATE284538T1 (de) Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzen
Castaman et al. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation
Possin et al. Cross-species translation of the Morris maze for Alzheimer’s disease
EP2293075A3 (de) Verfahren zur Diagnose neurodegenerativer Erkrankungen
Cho et al. PRSS1, SPINK1, CFTR, and CTRC pathogenic variants in Korean patients with idiopathic pancreatitis
El-Mezayen et al. Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study
ATE197964T1 (de) Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom
WO2000026668A3 (en) S100 proteins and autoantibodies as serum markers for cancer
Gurgey et al. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease
DE60331857D1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
WO2002029110A3 (en) Efficient tests of association for quantitative traits and affected-unaffected studies using pooled dna
JP2006300689A (ja) 肝疾患病態判定用マーカー及び該マーカーを用いる肝疾患病態判定方法
Morange et al. Ala147Thr and C+ 1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers
FI990380A0 (fi) Diagnostinen ja seulontamenetelmä
Durany et al. Increased frequency of the α‐1‐antichymotrypsin T allele in cerebral amyloid angiopathy
Bhakdi et al. A simple method for quantitative measurement of C3d in human plasma
Hota et al. Role of eosinophil count and neutrophil: lymphocyte count ratio as prognostic markers in patients with sepsis
ATE515576T1 (de) Protein c polymorphismen
DE60127901D1 (de) TCF-1 Nukleotidsequenzvariation
Dunn et al. Evaluation of role of factor V Leiden mutation in fatal pulmonary thromboembolism
TW200517502A (en) Methods for detecting Alzheimer's disease
ATE442456T1 (de) Verfahren zur bestimmung von zirkulierender dns in plasma und zum nachweis von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties